A U.K.-based biopharmaceutical company that just raised a new round of funding moved its corporate headquarters to Austin.
IntraBio Inc., which is developing drugs to treat neurodegenerative diseases, said March 26 that it raised over $40 million in new equity funding from a group of undisclosed investors. The money will help the company commercialize and launch a new drug that treats Niemann-Pick disease type C, a rare ailment passed down in families that impacts the body’s ability to break down fats.
The drug, currently called “1B1001,” has completed a Phase 3 trial. That recently paved the way for the U.S. Food and Drug Administration to accept the company’s new drug application.
Austin Business Journal